{"classes":[{"categories":[{"measurements":[{"comment":"Only 1 observation was equal or above LLoQ. Only Geometric Mean was reported, and Geometric Coefficient of Variation could not be calculated.","groupId":"OG000","spread":"NA","value":"619.0"},{"comment":"There were \\>2 observations, and no observation was equal or above LLoQ. Therefore, both Geometric Mean and Geometric Coefficient of Variation could not be calculated.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"There were \\>2 observations, and no observation was equal or above LLoQ. Therefore, both Geometric Mean and Geometric Coefficient of Variation could not be calculated.","groupId":"OG002","spread":"NA","value":"NA"},{"comment":"Only 1 observation was equal or above LLoQ. Only Geometric Mean was reported, and Geometric Coefficient of Variation could not be calculated.","groupId":"OG003","spread":"NA","value":"1430"},{"comment":"Only 1 observation was equal or above lower limit of quantification (LLoQ). Only Geometric Mean was reported, and Geometric Coefficient of Variation could not be calculated.","groupId":"OG004","spread":"NA","value":"931.0"},{"comment":"Only 1 observation was equal or above LLoQ. Only Geometric Mean was reported, and Geometric Coefficient of Variation could not be calculated.","groupId":"OG005","spread":"NA","value":"24400"},{"comment":"Only 1 observation was equal or above LLoQ. Only Geometric Mean was reported, and Geometric Coefficient of Variation could not be calculated.","groupId":"OG006","spread":"NA","value":"20500"},{"comment":"There were \\>2 observations, and no observation was equal or above LLoQ. Therefore, both Geometric Mean and Geometric Coefficient of Variation could not be calculated.","groupId":"OG007","spread":"NA","value":"NA"},{"comment":"There were \\>2 observations, and no observation was equal or above LLoQ. Therefore, both Geometric Mean and Geometric Coefficient of Variation could not be calculated.","groupId":"OG008","spread":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"28"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"21"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"20"},{"groupId":"OG008","value":"10"},{"groupId":"OG009","value":"0"}],"units":"Participants"}],"title":"Cycle 1/Day1-0 Hour"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28","value":"2723"},{"groupId":"OG001","spread":"26","value":"1536"},{"groupId":"OG002","spread":"25","value":"779.3"},{"groupId":"OG003","spread":"20","value":"1443"},{"groupId":"OG004","spread":"23","value":"1688"},{"groupId":"OG005","spread":"30","value":"2323"},{"groupId":"OG006","spread":"28","value":"2509"},{"groupId":"OG007","spread":"49","value":"2529"},{"groupId":"OG008","spread":"42","value":"4283"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"22"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"26"},{"groupId":"OG004","value":"32"},{"groupId":"OG005","value":"21"},{"groupId":"OG006","value":"8"},{"groupId":"OG007","value":"18"},{"groupId":"OG008","value":"9"},{"groupId":"OG009","value":"0"}],"units":"Participants"}],"title":"Cycle 1/Day15-0 Hour"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"30","value":"2114"},{"groupId":"OG001","spread":"29","value":"982.3"},{"groupId":"OG002","spread":"26","value":"743.2"},{"groupId":"OG003","spread":"145","value":"1627"},{"groupId":"OG004","spread":"72","value":"1547"},{"groupId":"OG005","spread":"38","value":"1351"},{"groupId":"OG006","spread":"29","value":"693.5"},{"groupId":"OG007","spread":"38","value":"1114"},{"groupId":"OG008","spread":"69","value":"928.0"},{"groupId":"OG009","spread":"48","value":"780.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"14"},{"groupId":"OG004","value":"18"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"10"},{"groupId":"OG008","value":"8"},{"groupId":"OG009","value":"8"}],"units":"Participants"}],"title":"Cycle 3/Day1-0 Hour"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"53","value":"2259"},{"groupId":"OG001","spread":"63","value":"1059"},{"groupId":"OG002","spread":"97","value":"931.9"},{"groupId":"OG003","spread":"33","value":"1281"},{"groupId":"OG004","spread":"37","value":"1366"},{"groupId":"OG005","spread":"25","value":"1417"},{"groupId":"OG006","spread":"14","value":"855.1"},{"groupId":"OG007","spread":"30","value":"1046"},{"groupId":"OG008","spread":"67","value":"906.7"},{"groupId":"OG009","spread":"38","value":"671.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"5"},{"groupId":"OG008","value":"6"},{"groupId":"OG009","value":"7"}],"units":"Participants"}],"title":"Cycle 5/Day1-0 Hour"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"54","value":"1840"},{"groupId":"OG001","spread":"21","value":"1726"},{"groupId":"OG002","spread":"38","value":"839.9"},{"groupId":"OG003","spread":"19","value":"1747"},{"groupId":"OG004","spread":"138","value":"2300"},{"groupId":"OG005","spread":"29","value":"1196"},{"comment":"Only 1 observation was equal or above LLoQ. Only Geometric Mean was reported, and Geometric Coefficient of Variation could not be calculated.","groupId":"OG006","spread":"NA","value":"1030"},{"comment":"Only 1 observation was equal or above LLoQ. Only Geometric Mean was reported, and Geometric Coefficient of Variation could not be calculated.","groupId":"OG007","spread":"NA","value":"1070"},{"groupId":"OG008","spread":"27","value":"669.0"},{"groupId":"OG009","spread":"30","value":"851.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"6"},{"groupId":"OG009","value":"6"}],"units":"Participants"}],"title":"Cycle 8/Day1-0 Hour"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"52","value":"1814"},{"groupId":"OG001","spread":"24","value":"1171"},{"groupId":"OG002","spread":"35","value":"690.2"},{"groupId":"OG003","spread":"39","value":"1172"},{"comment":"Only 1 observation was equal or above LLoQ. Only Geometric Mean was reported, and Geometric Coefficient of Variation could not be calculated.","groupId":"OG004","spread":"NA","value":"610.0"},{"groupId":"OG005","spread":"5","value":"1359"},{"comment":"There were \\<=2 participants, and no observation was equal or above LLoQ . Therefore, both Geometric Mean and Geometric Coefficient of Variation could not be calculated.","groupId":"OG007","spread":"NA","value":"NA"},{"groupId":"OG008","spread":"64","value":"655.4"},{"groupId":"OG009","spread":"23","value":"653.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"3"}],"units":"Participants"}],"title":"Cycle 12/Day1-0 Hour"}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"28"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"21"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"20"},{"groupId":"OG008","value":"10"},{"groupId":"OG009","value":"8"}],"units":"Participants"}],"description":"Ctrough is steady-state pre-dose concentration.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"During phase 1b participants with Non-Small Cell Lung Cancer (NSCLC) received utomilumab 500 mg intravenously (IV) every 4 weeks (Q4W) with 10 milligrams per kilogram (mg/kg) of avelumab administered IV every 2 weeks (Q2W) for 2 cycles, where each cycle was of 4 weeks.","id":"OG000","title":"Combination A Phase 1b NSCLC: Utomilumab 500 mg + Avelumab"},{"description":"During phase 1b participants with NSCLC received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"OG001","title":"Combination A Phase 1b NSCLC: Utomilumab 100 mg + Avelumab"},{"description":"During phase 1b participants with NSCLC received utomilumab 20 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"OG002","title":"Combination A Phase 1b NSCLC: Utomilumab 20 mg + Avelumab"},{"description":"During Phase 2 participants with melanoma received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"OG003","title":"Combination A Phase 2 Melanoma: Utomilumab 100 mg + Avelumab"},{"description":"During Phase 2 participants with Squamous Cell Carcinoma of the Head and Neck (SCCHN) received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"OG004","title":"Combination A Phase 2 SCCHN: Utomilumab 100 mg + Avelumab"},{"description":"During Phase 2 participants with Triple Negative Breast Cancer (TNBC) received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"OG005","title":"Combination A Phase 2 TNBC: Utomilumab 100 mg + Avelumab"},{"description":"During Phase 2 participants with Squamous cell lung cancer (SCLC) received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"OG006","title":"Combination A Phase 2 SCLC: Utomilumab 100 mg + Avelumab"},{"description":"During Phase 2 participants with NSCLC received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"OG007","title":"Combination A Phase 2 First Line (1L) NSCLC: Utomilumab 100 mg + Avelumab"},{"description":"During Phase 2 participants with NSCLC received utomilumab 100 mg IV Q4W for cycle 1 then utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W starting at cycle 2.","id":"OG008","title":"Combination A Phase 2 1L NSCLC: Utomilumab Then Utomilumab + Avelumab"},{"description":"During Phase 2 participants with NSCLC received avelumab 10 mg/kg administered IV Q2W for cycles 1 then utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W starting at cycle 2.","id":"OG009","title":"Combination A Phase 2 1L NSCLC: Avelumab Then Utomilumab + Avelumab"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All participants who received at least one dose of study drug and who had at least one of the PK concentrations for Avelumab, Utomilumab, PD 0360324, PF-04518600. Here, \"Number of participants analyzed'' signifies number of participants evaluable for this outcome measure, where \"Number Analyzed\" signifies number of participants evaluable for specified time points. For participants of ''Phase 2 1L NSCLC: Avelumab then Utomilumab + Avelumab'' reporting group PK sampling started from Cycle 3 Day 1.","reportingStatus":"POSTED","timeFrame":"Pre-dose on Day 1 of Cycles 1,3,5,8, and Cycle 12; Day 15 of Cycle 1 (non-dosing). For ''Phase 2 1L NSCLC: Avelumab then Utomilumab + Avelumab'' reporting group: Day 1 of Cycles 3,5,8 and 12","title":"Pre-Dose Observed Plasma Concentration (Ctrough) of Utomilumab in Combination A","type":"SECONDARY","unitOfMeasure":"Nanogram per milliliter"}